← back to search

Valentin Barsan

Stanford University · US
Area of research
Oncology · Genetics
Research interest
Research interests include CAR-T cell therapy research, Glioma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, and Immunotherapy and Immune Responses.
h-index
12
citations
1,821
works
34
NIH funding
primary concept
Medicine
email

Recent publications

CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology 2025cited by 0position: middledoi
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature 2024cited by 160position: middledoi
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature 2024cited by 12position: middledoi
Abstract 959: Immune signatures of GD2 CAR T cell activity in H3K27M+ diffuse midline glioma patients
Cancer Research 2023cited by 3position: middledoi
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
Nature 2022cited by 769position: middledoi
Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells
Nature Communications 2022cited by 42position: middledoi
Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Blood 2022cited by 4position: middledoi
508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition
Regular and Young Investigator Award Abstracts 2022cited by 1position: middledoi
Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas
Cancer Research 2021cited by 8position: middledoi
OMIC-11. SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+ DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY
Neuro-Oncology 2021cited by 3position: middledoi
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
Journal for ImmunoTherapy of Cancer 2019cited by 88position: middledoi
Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience
Cureus 2019cited by 13position: firstdoi
Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience
Journal of Pediatric Hematology/Oncology 2018cited by 54position: middledoi
Long-term follow-up and pregnancy after complete sacrectomy with lumbopelvic reconstruction: case report and literature review
BMC Pregnancy and Childbirth 2016cited by 434position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

John R. Crawford · Children's Hospital of Orange County2 papers (2018–2019)Denise Malicki · University of California, San Diego2 papers (2018–2019)Jennifer Elster · University of San Diego2 papers (2018–2019)Hamza Gorsi · Central Michigan University2 papers (2018–2019)M. Kyle Cromer · Gladstone Institutes1 papers (2022–2022)Erik Wennerberg · Institute of Cancer Research1 papers (2022–2022)Cara Haymaker · The University of Texas MD Anderson Cancer Center1 papers (2022–2022)Lanipua Yeh‐Nayre · Rady Children's Hospital-San Diego1 papers (2018–2018)Heather M. McGee · City Of Hope National Medical Center1 papers (2022–2022) · 1 papers (2022–2022)Yana G. Najjar · UPMC Hillman Cancer Center1 papers (2022–2022)Daniel K. Wells · Parker Institute for Cancer Immunotherapy1 papers (2022–2022) · 1 papers (2022–2022)Megan Paul · Palo Alto University1 papers (2019–2019)Mehrzad Milburn · University of California San Diego1 papers (2018–2018)Roberta Zappasodi · Cornell University1 papers (2022–2022)Steven Vensko · North Carolina State University1 papers (2022–2022)Dante S. Bortone · University of North Carolina at Chapel Hill1 papers (2022–2022)Randy F. Sweis · University of Illinois Chicago1 papers (2022–2022)Houssein Abdul Sater · ABS Consulting (United States)1 papers (2022–2022)